Literature DB >> 19447616

Antimalarial activity of thiosemicarbazones and purine derived nitriles.

Jeremy P Mallari1, Wendyam A Guiguemde, R Kiplin Guy.   

Abstract

Malaria is a devastating illness caused by multiple species of the Plasmodium genus. The parasite's falcipain proteases have been extensively studied as potential drug targets. Here we report the testing of two established cysteine protease inhibitor scaffolds against both chloroquine sensitive and chloroquine resistant parasites. A subset of purine derived nitriles killed the parasite with moderate potency, and these inhibitors do not seem to exert their antiproliferative effects as cysteine protease inhibitors. Compound potency was determined to be similar against both parasite strains, indicating a low probability of cross resistance with chloroquine. These compounds represent a novel antimalarial scaffold, and a potential starting point for the development new inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447616      PMCID: PMC2744305          DOI: 10.1016/j.bmcl.2009.04.142

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  37 in total

1.  Observations on two Plasmodium falciparum infections with an abnormal response to chloroquine.

Authors:  D V MOORE; J E LANIER
Journal:  Am J Trop Med Hyg       Date:  1961-01       Impact factor: 2.345

2.  Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.

Authors:  Eva Altmann; Sandra W Cowan-Jacob; Martin Missbach
Journal:  J Med Chem       Date:  2004-11-18       Impact factor: 7.446

3.  Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives.

Authors:  José N Domínguez; Caritza León; Juan Rodrigues; Neira Gamboa de Domínguez; Jiri Gut; Philip J Rosenthal
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

4.  Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents.

Authors:  Nicola Micale; Alan P Kozikowski; Roberta Ettari; Silvana Grasso; Maria Zappalà; Jong-Jin Jeong; Ajay Kumar; Manjit Hanspal; Athar H Chishti
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

5.  Screening of protease inhibitors as antiplasmodial agents. Part I: Aziridines and epoxides.

Authors:  Franziska Schulz; Christoph Gelhaus; Björn Degel; Radim Vicik; Saskia Heppner; Alexander Breuning; Matthias Leippe; Jiri Gut; Philip J Rosenthal; Tanja Schirmeister
Journal:  ChemMedChem       Date:  2007-08       Impact factor: 3.466

6.  Antimalarial synergy of cysteine and aspartic protease inhibitors.

Authors:  A Semenov; J E Olson; P J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems.

Authors:  Jun Liu; Eva S Istvan; Ilya Y Gluzman; Julia Gross; Daniel E Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

8.  Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives.

Authors:  Idan Chiyanzu; Cailean Clarkson; Peter J Smith; Julie Lehman; Jiri Gut; Philip J Rosenthal; Kelly Chibale
Journal:  Bioorg Med Chem       Date:  2005-05-02       Impact factor: 3.641

9.  Application of multicomponent reactions to antimalarial drug discovery. Part 2: New antiplasmodial and antitrypanosomal 4-aminoquinoline gamma- and delta-lactams via a 'catch and release' protocol.

Authors:  Chitalu C Musonda; Jiri Gut; Philip J Rosenthal; Vanessa Yardley; Renata C Carvalho de Souza; Kelly Chibale
Journal:  Bioorg Med Chem       Date:  2006-05-11       Impact factor: 3.641

10.  Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain.

Authors:  Naoaki Fujii; Jeremy P Mallari; Elizabeth J Hansell; Z Mackey; Patricia Doyle; Y M Zhou; Jiri Gut; Philip J Rosenthal; James H McKerrow; R Kiplin Guy
Journal:  Bioorg Med Chem Lett       Date:  2005-01-03       Impact factor: 2.823

View more
  5 in total

1.  Automated high-throughput system to fractionate plant natural products for drug discovery.

Authors:  Ying Tu; Cynthia Jeffries; Hong Ruan; Cynthia Nelson; David Smithson; Anang A Shelat; Kristin M Brown; Xing-Cong Li; John P Hester; Troy Smillie; Ikhlas A Khan; Larry Walker; Kip Guy; Bing Yan
Journal:  J Nat Prod       Date:  2010-04-23       Impact factor: 4.050

2.  Trypanocidal and cytotoxic evaluation of synthesized thiosemicarbazones as potential drug leads against sleeping sickness.

Authors:  Bienvenu Glinma; Sika D S Kpoviessi; Fernand A Gbaguidi; Coco N Kapanda; Joanne Bero; Joëlle Quetin-Leclercq; Mansourou Moudachirou; Jacques Poupaert; Georges C Accrombessi; Emma W Gachomo; Lamine Baba-Moussa; Simeon O Kotchoni
Journal:  Mol Biol Rep       Date:  2014-01-10       Impact factor: 2.316

3.  Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei.

Authors:  Glaécia An Pereira; Lucianna H Santos; Steven C Wang; Luan C Martins; Filipe S Villela; Weiting Liao; Marco A Dessoy; Luiz C Dias; Adriano D Andricopulo; Mariana Af Costa; Ronaldo Ap Nagem; Conor R Caffrey; Klaus R Liedl; Ernesto R Caffarena; Rafaela S Ferreira
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

4.  Synthesis and Biological Evaluation of New Thiosemicarbazone Derivative Schiff Bases as Monoamine Oxidase Inhibitory Agents.

Authors:  Betül Kaya Çavuşoğlu; Begüm Nurpelin Sağlık; Derya Osmaniye; Serkan Levent; Ulviye Acar Çevik; Abdullah Burak Karaduman; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  Molecules       Date:  2017-12-28       Impact factor: 4.411

5.  Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors.

Authors:  G D Kishore Kumar; Gustavo E Chavarria; Amanda K Charlton-Sevcik; Wara M Arispe; Matthew T Macdonough; Tracy E Strecker; Shen-En Chen; Bronwyn G Siim; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem Lett       Date:  2010-01-06       Impact factor: 2.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.